The average reduction in AHI calculated across low, mid, and high-dose IHL-42X has met our expectations for what would constitute a valuable product for the treatment of obstructive sleep apnoea.
BOOOOM !
- Forums
- ASX - By Stock
- Ann: IHL-42X positive phase 2 clinical trial results
The average reduction in AHI calculated across low, mid, and...
-
- There are more pages in this discussion • 351 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)